Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Second TomoTherapy Hi·Art Treatment System To Be Installed At Addenbrooke’s Hospital

TomoTherapy Incorporated announced that Addenbrooke’s Hospital of Cambridge, England, will install their second TomoTherapy Hi•Art radiation therapy system in 2009. Addenbrooke during 2007 was selected to be the first National Health Service (NHS) hospital in England to treat cancer patients with TomoTherapy’s unique, CT platform-based radiation therapy solution. On Oct. 31, 2007 the first patient was treated with TomoTherapy technology at Addenbrooke’s. After just six months, Addenbrooke’s decided that they needed a second Hi•Art treatment system, mainly due to the quality of treatment they could then offer to more cancer patients. Dr Neil Burnet, Lead Clinical Oncologist for the TomoTherapy project at Addenbrooke’s comments: “The TomoTherapy project here has been an enormous success, particularly due to the team that we have been able to establish. TomoTherapy has proved a highly efficient solution for daily image-guided radiotherapy with positional correction, and the delivery of sophisticated treatment plans using high quality, intensity-modulated radiotherapy… We are delighted that we will soon double our capacity so that these technologies can be offered to more patients.” TomoTherapy technology is developed and manufactured by TomoTherapy Inc and is supplied in the UK by Oncology Systems Limited. Says Julie Mead, Clinical Advisor and Director at Oncology Systems: “This is the strongest commendation of TomoTherapy technology possible. Creating a clinical-business case for new, ‘high end’ equipment in the NHS, without any financial reimbursement, is always a challenge. The fact that Addenbrooke’s so quickly decided to install their second TomoTherapy unit, and from local funding, is a testament to their belief in this technology, which not only offers the highest quality of treatment for significant cohorts of patients, but also a very cost-effective way of introducing advanced image guided and intensity modulated radiotherapy.” “We are very pleased that, after an objective clinical evaluation of the technology, Addenbrooke’s has chosen to install a second Hi•Art system,” says Fred Robertson, TomoTherapy CEO. “We look forward to partnering with Addenbrooke’s to broaden their radiotherapy reach in 2009.”